-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Choosing a Systemic Therapy for Advanced Mycosis Fungoides and Sezary Syndrome

Program: Education Program
Session: Practical Management of T-Cell and Natural Killer Cell Lymphomas
Saturday, December 5, 2015, 9:30 AM-11:00 AM
Hall D, Level 2 (Orange County Convention Center)
Sunday, December 6, 2015, 7:30 AM-9:00 AM
Hall E2, Level 2 (Orange County Convention Center)

Madeleine Duvic, MD

Dept. of Dermatology, M.D. Anderson Cancer Center, Houston, TX

Disclosures: Off Label Use: Most drugs used to treat CTCL are not FDA approved for that indication: steriods, soriatiane, interferons, gemcitibine, velcaide, lenalidimid, campath, doxil, and combination chemotherapy..

See more of: Practical Management of T-Cell and Natural Killer Cell Lymphomas
See more of: Education Program
Previous Presentation | Next Presentation >>